Please login to the form below
monalizumab
This page shows the latest monalizumab news and features for those working in and with pharma, biotech and healthcare.
Innate Pharma and AstraZeneca take monalizumab into phase 3
Innate Pharma’s lead candidate monalizumab – which is licensed by AstraZeneca – is heading for a pivotal phase 3 clinical trial. . ... The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in
Latest news
-
France’s Innate Pharma eyes $100m Nasdaq IPO
Some of the proceeds will go towards Innate’s lead candidate monalizumab, an anti-NKG2A antibody which was licensed by AstraZeneca last year in a deal that included $100m in ... The French biotech licensed co-commercial rights to the drug at the same
-
AZ invests more in IO with Transgene oncolytic virus deal
It signed a deal with France’s Innate Pharma last October (centred on its anti-NKG2A antibody, monalizumab (IPH2201), and yesterday added an alliance with another French biotech, Transgene.
-
AZ swells immuno-oncology pipeline with Innate deal
The main subject of the deal is Innate’s anti-NKG2A antibody, monalizumab (IPH2201), which targets a pathway thought to inhibit the activity of natural killer (NK) and cytotoxic T-cells ... for an option on anti-CD39 candidate IPH5201, which is in
-
Bad news for Innate Pharma as BMS-backed drug stumbles
Innate is also developing another checkpoint inhibitor - a CD94/NKG2A targeting antibody called monalizumab - as a monotherapy and in combination with AZ’s recently-approved PD-L1 inhibitor Imfinzi (durvalumab).
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
